Similarly, significant prognostic differences were observed in other in-house cohorts using IHC, and the survival time for patients with glioma with high TANK expression was shorter than that of patients with low TANK expression (PFS, HR=2.96 (1.48-5.94); OS, HR=2.45 (1.37-4.39); log-rank test P < 0.05, Figures 2K, L). The gene discussed is TANK; the disease is glioma.